Zusammenfassung Hintergrund Der Ausbruch der COVID-19-Erkrankung und die rasche Ausbreitung des sie verursachenden Coronavirus SARS-CoV‑2 bedroht weltweit nicht nur die physische, sondern auch die psychische Gesundheit der Bevölkerung. Seine Auswirkungen auf Neuerkrankungen und die Entwicklung bestehender Erkrankungen im ambulanten psychiatrischen Bereich in Deutschland ist noch nicht untersucht. Methoden Die Dokumentation in den Akten von 682 behandelten psychisch erkrankten Personen wurde retrospektiv bezüglich ihrer subjektiv erlebten Belastung durch die Pandemie und der klinischen Relevanz hin untersucht. Ergebnisse Bei 60,5 % (n = 378) bestand eine psychische Belastung durch diese Pandemie. 14,5 % (n = 99) der Betroffenen litten unter Angst vor dem Virus SARS-CoV‑2 und einer möglichen Infektion, 25,5 % (n = 174) unter den getroffenen Schutzmaßnahmen (Lockdown) und 4,3 % (n = 29) unter beidem; hierbei bestanden signifikante diagnoseabhängige Unterschiede. Angsterkrankte waren signifikant stärker belastet und hatten mehr Angst vor der Erkrankung, Psychoseerkrankte waren signifikant weniger belastet. Bei 43,7 % aller dieser Belasteten (n = 132) wurde eine akute therapeutische Intervention erforderlich, 6,0 % (n = 18) mussten stationär eingewiesen werden. Diskussion Psychisch Vorerkrankte gehören zu den durch die Belastungen der COVID-19-Pandemie besonders gefährdeten Bevölkerungsgruppen. Langfristigere Untersuchungen zum Verlauf der psychischen Belastungen unter Pandemiemaßnahmen sowie Studien zur Förderung von Resilienz in dieser Bevölkerungsgruppe und die Implementierung solcher Maßnahmen sind erforderlich.
Background : The COVID-19 pandemic is presumably having an impact on the consumption of psychoactive substances. Social distancing and lockdown measures may particularly affect the use of “party drugs” (e.g., stimulants, dissociatives, and GHB/GBL) through the absence of typical use settings. We aimed to analyse the use patterns of those substances and underlying motivations before and during the pandemic. Methods : A subsample of 1,231 users of stimulants (amphetamine, methamphetamine, MDMA/ecstasy, cocaine), dissociative drugs (ketamine, dextromethorphan, PCP), and GHB/GBL was assessed from 30 th April to 4 th August 2020 as part of the Corona Drug Survey , a cross-sectional international online survey in five languages that included a total of 5,049 participants. The reported use of distinct substances and the underlying motivations were ascertained before (retrospectively) and during the pandemic. Furthermore, associations between drug use as a coping mechanism, pandemic-related stressors, and substance use were examined. Results : Regarding the reported frequency of use during the pandemic, 48.0–64.8% of the sample ceased or decreased, 11.9–25.5% maintained, and 23.6–29.1% increased their consumption. MDMA/ecstasy showed the strongest decrease and GHB/GBL and dissociatives the highest increase. Participants reported that price, quality, and supply were mostly unaffected by the pandemic. The most common motivations before and during the pandemic were mood-related factors, such as a desire to feel exhilarated, euphoric, high, or buzzed. The relevance of social purposes and mood-related motivators declined during the pandemic, whereas dealing with boredom increased. Overall, 16.4–35.6% perceived drug use as helpful for dealing with pandemic-related stressors, which were associated with an increased consumption frequency. Conclusion : The early stage of the COVID-19 pandemic was associated with major changes in the use of “party drugs”. Those who increased their level of drug use and perceived it as a coping strategy in particular might be targeted with adaptive preventive and therapeutic measures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.